Effects of navelbine and docetaxel on gene expression in lung cancer cell strains.
OBJECTIVE
To search genes sensitivity to the anti-cancer drugs navelbine (NVB) and docetaxel (DOC) in small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) cell strains.


METHODS
The sensitivity of 4 strains of SCLC and 6 strains of NSCLC to NVB and DOC was evaluated using the MTT assay. The expression of 1291 sensitive-related genes to the anti-cancer drugs in 10 lung cancer cell strains was measured using cDNA macroarrays and the relationship was analyzed.


RESULTS
In total, there were 56 (r > or = 0.4) genes sensitive to NVB and DOC. For NVB: 36 genes were sensitive to NVB, 20 co-expressed genes between the SCLC+NSCLC set and the NSCLC set; 27 expressed genes and 7 specially expressed genes in the SCLC+NSCLC set; and 29 expressed genes and 9 specially expressed genes in the NSCLC set. For DOC, 50 genes were sensitive to DOC, 12 co-expressed genes between the SCLC+NSCLC set and the NSCLC set; 24 expressed genes and 12 specially expressed genes in the SCLC+NSCLC set; and 38 expressed genes and 26 specially expressed genes in the NSCLC set. The genes sensitive to NVB and DOC in lung-cancer cell stains were mainly divided into the following 4 categories: signal transduction molecules, cell factors, transcription factors and metabolism-related enzymes and inhibitors.


CONCLUSIONS
There were obvious differences in genes related to NVB and DOC between SCLC and NSCLC cell strains, but the same as categories of function.
Cai
Li
L
Internal Medicine of Oncology, the Third Affiliated Hospital of Harbin Medical University, Harbin 150040, China. caiwenxin76@yahoo.com.cn
Dong
Hai-ying
HY
Sui
Guang-jie
GJ
D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000473:pathology; D018288:Carcinoma, Small Cell / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D016000:Cluster Analysis; D051152:Clusterin / Q000235:genetics; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D037483:Galectin 1 / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D020128:Inhibitory Concentration 50; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology; D008668:Metallothionein / Q000235:genetics; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D043823:Taxoids / Q000494:pharmacology*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000235:genetics; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077235:Vinorelbine
D000972:Antineoplastic Agents, Phytogenic; D051152:Clusterin; D037483:Galectin 1; D043823:Taxoids; D019715:Tissue Inhibitor of Metalloproteinase-1; D000077143:Docetaxel; D014747:Vinblastine; D008668:Metallothionein; D000077235:Vinorelbine